Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Comprehensive genomic characterization of patient tumours has the potential to advance therapies and inform basic cancer research. In this Comment, David B. Solit and colleagues provide their personal perspective on the implementation of an enterprise-wide, prospective clinical sequencing strategy and make a call for a universal approach to next-generation sequencing-based tumour profiling.
In this Comment, the authors outline the emerging rationale for the clinical use of tumour budding, a histological manifestation of tumour cell invasion, as a diagnostic tool and biomarker in colorectal cancer.
